{"schema_version":"secwatch.filing_event.v1","accession":"0000879169-23-000014","form_type":"8-K","ticker":"INCY","cik":"0000879169","company_name":"INCYTE CORP","filed_at":"2023-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.528370+00:00","generated_at":"2026-06-16T04:21:52.059214+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Incyte Q1: Jakafi rev $580M (+7%); Opzelura $57M (+343%); raises Jakafi FY guidance to $2.55-2.63B","bullets":["Total net product revenues $693M (+14% YoY); total GAAP revenues $808.7M (+10% YoY).","GAAP net income $21.7M ($0.10 diluted EPS) vs $38.0M ($0.17) in Q1 2022; Non-GAAP net income $84.6M ($0.37).","Jakafi FY 2023 guidance raised: bottom end to $2.55B from $2.53B; new range $2.55-$2.63B.","FDA issued complete response letter for ruxolitinib XR (once-daily) in MF, PV, GVHD; next steps unclear.","Discontinued parsaclisib combo trials in MF (LIMBER-304/313) and development in wAIHA; axatilimab Phase 2 cGVHD data on track for mid-2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000879169-23-000014","json":"https://secwatch.observer/filing/0000879169-23-000014.json","markdown":"https://secwatch.observer/filing/0000879169-23-000014.md","text":"https://secwatch.observer/filing/0000879169-23-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879169/000087916923000014/0000879169-23-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879169/000087916923000014/incy-20230502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T04:21:52.059214+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"73b362e26fe0abb9bc07285910fa711999e221a1","claim":"INCYTE CORP reported first fiscal quarter ended March 31, 2023 results: revenue $693 million. Guidance raised.","evidence_excerpt":"FOR IMMEDIATE RELEASE Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs – Total net product revenues of $693 million in Q1'23 (+14% Y/Y) – Jakafi ® (ruxolitinib) net product revenues of $580 million (+7% Y/Y) in Q1'23; raising the bottom end of full year guidance to new range of $2.55 - $2.63 billion for FY 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/879169/000087916923000014/0000879169-23-000014-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first fiscal quarter ended March 31, 2023"},{"label":"Revenue","value":"$693 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}